Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IFN-SARS-CoV
- Development stage
- Preclinical
- Lead developer
- Canthevac
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
IFN-SARS-CoV (also known as the IBIS construct) is a preclinical-stage interferon-integrated vaccine candidate being developed by Canthevac for the prevention of COVID-19 and SARS. Utilizing Canthevac's proprietary Interferon-integrated Vaccine Platform (IVP), the vaccine incorporates interferon activity directly into a live-attenuated viral vector construct targeting SARS-CoV and SARS-CoV-2. Administered intranasally, the vaccine is designed to infect respiratory epithelial cells and trigger the release of interferon, thereby activating local antiviral defenses and boosting mucosal T-cell and B-cell immunity while preventing further replication of the vaccine virus for safety.
- Other names
- IBIS
02
Targets
IFNLR (Interferon lambda receptor complex)IFNGR1 (Interferon gamma receptor)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on IFN-SARS-CoV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IFN-SARS-CoV.